secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089549
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics appoints Gina Chapman to board effective Sept 1, 2023
--------------------------------------------------------------------------

- Gina Chapman, President and CEO of CARGO Therapeutics, joins as Class III director.
- Effective Sept 1, 2023; also appointed to Nominating and Corporate Governance Committee.
- Initial equity grant of $500K value (32,000 shares of common stock) vesting over 3 years.
- Annual director fee of $40,000 plus $4,000 for committee service; standard indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923089549/0001104659-23-089549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923089549/tm2323293d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer